Medicure (CVE:MPH) Sets New 1-Year High – Time to Buy?

by · The Markets Daily

Shares of Medicure Inc. (CVE:MPH – Get Free Report) reached a new 52-week high on Monday. The stock traded as high as C$4.39 and last traded at C$4.30, with a volume of 5,901 shares traded. The stock had previously closed at C$4.25.

Medicure Stock Up 2.3%

The company has a current ratio of 0.97, a quick ratio of 1.28 and a debt-to-equity ratio of 6.02. The stock has a market cap of C$45.92 million, a P/E ratio of -6.11 and a beta of 0.98. The firm has a 50-day simple moving average of C$2.56 and a two-hundred day simple moving average of C$1.66.

Medicure Company Profile

(Get Free Report)

Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.

Further Reading